Compare VAC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAC | ADPT |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | 624 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2011 | 2019 |
| Metric | VAC | ADPT |
|---|---|---|
| Price | $75.27 | $13.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $75.13 | $17.78 |
| AVG Volume (30 Days) | 412.0K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $5,032,000,000.00 | $276,976,000.00 |
| Revenue This Year | $54.23 | $3.98 |
| Revenue Next Year | $2.90 | $22.72 |
| P/E Ratio | $116.58 | ★ N/A |
| Revenue Growth | 1.31 | ★ 54.77 |
| 52 Week Low | $44.58 | $8.97 |
| 52 Week High | $86.33 | $20.76 |
| Indicator | VAC | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 50.69 |
| Support Level | $74.07 | $12.22 |
| Resistance Level | $80.43 | $15.27 |
| Average True Range (ATR) | 3.63 | 0.78 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 65.23 | 52.13 |
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.